Which are the most promising new medications in phase 3 clinical trials for the treatment of painful large joint arthritis?
What is the role of transdermal fentanyl patches in management of cancer pain?
Towards a better understanding of interstitial lung diseases associated with autoimmune rheumatic diseases - Optimising the monitoring and treatment of SSc-ILD
Highlights of the 2019 EASD Congress
DAPA HF : The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial
Early intervention with oral semaglutide and long term safety
VERIFY and CONCLUDE study
Clinical properties and differences between GLP-1 agonists
Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes
Diabetic retinopathy: Is the eye a mirror of the brain?
Cardiovascular risk factors
Leading role of hypertension in CV risk scene
Controversial issues in guidelines
Cardiovascular mode of action of GLP-1 receptor agonists
Exploring the effects of SGLT2 inhibition in ongoing clinical trials
Medical Devices in Diabetes
Will SGLT2-inhibitors change the landscape?
Innate immunity in pancreatic islet inflammation
The artificial beta cell. When will the dream become reality?
Observational study of insulin pump treatment
The evidence for metformin is unclear?
The ORIGIN Study And Legacy Effects
EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk
Principal investigator presenting the results of EMPA-REG OUTCOME trial
Mathematic modelling of fibrinolysis
Pre and perioperative factors modulate fibrinolysis in arthroplasty patients
Cellular and mechanical modulators of fibrin structure
Platelets, NETs and Immunity
Mechanisms by which DNA, histones and NETs stabilise clots
Free fatty acids modulate thrombin activity ov fibrinogen and destabilise fibrin clots
Genetics of thrombosis
Prof. Giuseppe Mancia receives the Excellence Research Award
EULAR 2020 E-Congress Report
PAINWeek has gone virtual
The EULAR 2020 E-Congress programme is now available online